<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-INR-16010071</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2016-12-02</date_registration>
      <primary_sponsor>Xinqiao Hospital, Chongqing</primary_sponsor>
      <public_title>Clinical trial of Priming with Recombinant Human Granulocyte ColonyeStimulating Factor on low dose Decitabine combined with Busulfex and Cyclophosphamide for High-Risk Acute Myeloid Leukemia Patients Undergoing Human Leukocyte Antigene Matched Hematopoietic Stem Cell Transplantation</public_title>
      <acronym />
      <scientific_title>Effect of Priming with Recombinant Human Granulocyte ColonyeStimulating Factor on low dose Decitabine combined with Busulfex and Cyclophosphamide for High-Risk Acute Myeloid Leukemia Patients Undergoing Human Leukocyte Antigene Matched Hematopoietic Stem Cell Transplantation：A Multicenter,Open,Randomized controlled trial </scientific_title>
      <Scientific_acronym />
      <date_enrolment>2016-12-15</date_enrolment>
      <type_enrolment />
      <target_size>Test group:97;Control group:97;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=16676</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>Acute myeloid leukemia</hc_freetext>
      <i_freetext>Test group:G-CSF 150ug  qd -13d to -8d; Decitabine 20mg/m2 qd -12d to -8d, Bu 0.8mg/kg q6h d-7 to d-4, CTX 60mg/kg d-3 to d-2;Control group:Bu 0.8mg/kg q6h d-7 to d-4, CTX 60mg/kg d-3 to d-2;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Li Gao</firstname>
        <middlename />
        <lastname />
        <address>183 Xinqiao Main Street, Chongqing, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13228686076</telephone>
        <email>gaotiantiantiger@163.com</email>
        <affiliation>Xinqiao Hospital, Chongqing </affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Xi Zhang</firstname>
        <middlename />
        <lastname />
        <address>183 Xinqiao Main Street, Chongqing, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13808310064</telephone>
        <email>zhangxxi@sina.com</email>
        <affiliation>Xinqiao Hospital, Chongqing </affiliation>
      </contact>
    </contacts>
    <countries>
      <country2 />
    </countries>
    <criteria>
      <inclusion_criteria>1. Patients with high risk AML, no limit on the gender, aged&lt;60years;
2. KPS score&gt;60, Estimated lifetime&gt;3months;  
3. Patients have HLA matched donor;
4. No serious impairment of important organs; Cr＜1.5mg/dl, Alb≧35g/L, Heart ejection index&gt;55%, Hb&gt;9g/dL, Bilirubin＜2.0mg/dl;
5. No other contraindication of hematopoietic stem cell transplantation;
6. Voluntary participants, informed consent.</inclusion_criteria>
      <agemin />
      <agemax>60</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Severe cardiac, renal or hepatic dysfunction;
2. Patients have other malignant cancer and must receive treatment;
3. Patients cant understand or follow study protocol due to clinical symptoms of brain dysfunction or serious mental illness;
4. Patients cant guarantee to accomplish treatment plan and follow-up;
5. Patients with severe  acute hypersensitive reaction;
6. Uncontrolled active infection;
7. Patients who have been enrolled in other clinical trial;
8. Patients arent suitable for this clinical trial according to investigators judgement.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>rate of relapse;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>overall survival;Leukemia free survival;rate of acute graft versus host disease;rate of chronic graft versus host disease;rate of side effects;treatment related mortality;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Chinese National Natural Science81500147</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-11-28</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>